Please assess the completion status of the following clinical trial:

Trial Title: Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients age \>18 year with previous diagnosis of Diabetes Mellitus and previous admission for DKA in any facility within the prior 2 years who meet the criteria for DKA at the time of admission and are willing to participate in the study protocol will be enrolled in the study.~DKA is defined as:~1. Serum bicarbonate below 18 mg/dl~2. Anion Gap over greater than or equal to 16~3. Serum ketones or beta hydroxybutyrate elevation \> 3 mmol/L~4. Serum glucose greater than or equal to 250 mg/dl~Exclusion Criteria:~Patients with no previous DKA, patients who are not willing to consent to participate in the study protocol for 1 year, pregnant women, dementia, and end stage renal disease on dialysis.~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Degludec (Type: EXPERIMENTAL): Discharge on once a day degludec insulin by pen (supplied by Novo) at dose 0.3 U/kg with reduction to 0.2 U/kg for GFR \<30 ml/hr.
- Standard long-acting (Type: ACTIVE_COMPARATOR): Discharge on 0.3 U/kg of admission long acting insulin glargine or detemir (provided by diabetes and endocrine clinic) regardless of their home insulin regimen at the time of admission with reduction to 0.2 U/kg in CKD with GFR \<30 ml/hr.

Based on this trial design, predict the completion outcome and termination type (if applicable).